What's Happening?
Latus Bio, a biotechnology company focused on gene therapies, has appointed Bethany Mancilla as its new Chief Business Officer. Mancilla brings over 25 years of experience in business development and corporate strategy, particularly in gene therapy and central
nervous system (CNS) drug development. Her appointment comes as Latus Bio prepares to advance its LTS-201 therapy for Huntington's disease into clinical trials. Mancilla's extensive background includes leadership roles at Capsida Biotherapeutics, Cue Biopharma, Kite Pharma, and Amgen, where she was instrumental in securing significant funding and strategic partnerships.
Why It's Important?
Bethany Mancilla's appointment is a strategic move for Latus Bio as it transitions into a clinical-stage company. Her expertise in gene therapy and CNS disorders is expected to drive the company's growth and enhance its pipeline of disease-modifying therapies. This development is crucial for Latus Bio's efforts to address high unmet medical needs, particularly in the field of Huntington's disease. Mancilla's leadership could lead to new partnerships and funding opportunities, positioning Latus Bio as a key player in the biotechnology sector. Her role will be pivotal in expanding the company's reach and impact in the gene therapy market.
